Login to Your Account



Gilead Sets the Bar at 100% for Interferon-Free HCV Regimen

By Catherine Shaffer
Staff Writer

Tuesday, November 13, 2012
Gilead Sciences Inc. reported stunning interim results from its Phase II ELECTRON study of 12 weeks of therapy with investigational hepatitis C (HCV) combo sofosbuvir (GS-7977) and GS-5885 with ribavirin showing the best-possible results at four weeks after treatment, a 100 percent sustained virologic response (SVR4).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription